Skip to main content
Erschienen in: Clinical Rheumatology 5/2011

01.05.2011 | Brief Report

Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis

verfasst von: Laura Muntean, Marena Rojas-Vargas, Pilar Font, Siao-Pin Simon, Simona Rednic, Ruxandra Schiotis, Simona Stefan, Maria M. Tamas, Horatiu D. Bolosiu, Eduardo Collantes-Estévez

Erschienen in: Clinical Rheumatology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study is to evaluate bone mineral density (BMD) and bone turnover markers in men with ankylosing spondylitis (AS) and to determine their relationship with clinical features and disease activity. Serum carboxi terminal cross-linked telopeptide of type I collagen (CTX), osteocalcin (OC) levels, and BMD of lumbar spine and proximal femur were evaluated in 44 males with AS, 18–60 years of age, and compared with those of 39 age-matched healthy men. Men with AS had a significantly lower BMD at the femoral neck and total hip as compared to age-matched controls (all p < 0.01). Osteopaenia or osteoporosis was found in 59.5% AS patients at the lumbar spine and in 47.7% at the femoral neck. Mean serum levels of OC and CTX were similar in AS patients and controls. There were no significant differences in BMD and bone turnover markers when comparing subgroups stratified according to disease duration or presence of peripheral arthritis. No correlations were found between disease activity markers and BMD or OC and CTX. In a cohort of relatively young males with AS, we found a high incidence of osteopaenia and osteoporosis. Disease activity and duration did not show any significant influence on BMD or serum levels of OC and CTX.
Literatur
1.
Zurück zum Zitat Toussirot E, Wendling D (2000) Bone mass in ankylosing spondylitis. Clin Exp Rheumatol 18(Suppl 21):S16–S20 Toussirot E, Wendling D (2000) Bone mass in ankylosing spondylitis. Clin Exp Rheumatol 18(Suppl 21):S16–S20
2.
Zurück zum Zitat Wendling D (2007) Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis? J Rheumatol 34:1647–1649PubMed Wendling D (2007) Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis? J Rheumatol 34:1647–1649PubMed
3.
Zurück zum Zitat Marhoffer W, Schatz H, Stracke H et al (1991) Serum osteocalcin levels in rheumatoid arthritis: a marker for accelerated bone turnover in late onset rheumatoid arthritis. J Rheumatol 18:1158–1162PubMed Marhoffer W, Schatz H, Stracke H et al (1991) Serum osteocalcin levels in rheumatoid arthritis: a marker for accelerated bone turnover in late onset rheumatoid arthritis. J Rheumatol 18:1158–1162PubMed
4.
Zurück zum Zitat Rosen HN, Moses AC, Garber J et al (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100–103PubMedCrossRef Rosen HN, Moses AC, Garber J et al (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100–103PubMedCrossRef
5.
Zurück zum Zitat Van Der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef Van Der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef
6.
Zurück zum Zitat Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Disease Activity Index. J Rheumatol 21:2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Disease Activity Index. J Rheumatol 21:2286–2291PubMed
7.
Zurück zum Zitat Calin A, Garret S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 21:2281–2285PubMed Calin A, Garret S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 21:2281–2285PubMed
8.
Zurück zum Zitat World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. WHO, Geneva World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. WHO, Geneva
9.
Zurück zum Zitat Donnelly S, Doyle DV, Denton A et al (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53:117–121PubMedCrossRef Donnelly S, Doyle DV, Denton A et al (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53:117–121PubMedCrossRef
10.
Zurück zum Zitat Capaci K, Hepguler S, Argin M et al (2003) Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med J 44:379–384PubMed Capaci K, Hepguler S, Argin M et al (2003) Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med J 44:379–384PubMed
11.
Zurück zum Zitat Baek HJ, Kang SW, Lee YJ et al (2005) Osteopenia in men with mild and severe ankylosing spondylitis. Rheumatol Int 26:30–34PubMedCrossRef Baek HJ, Kang SW, Lee YJ et al (2005) Osteopenia in men with mild and severe ankylosing spondylitis. Rheumatol Int 26:30–34PubMedCrossRef
12.
Zurück zum Zitat Geusens P, Vosse D, van der Linden S (2007) Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 19:335–339PubMedCrossRef Geusens P, Vosse D, van der Linden S (2007) Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 19:335–339PubMedCrossRef
13.
Zurück zum Zitat Bessant R, Keat A (2002) How should clinicians manage osteoporosis in ankylosing spondylitis? J Rheumatol 29:1511–1519PubMed Bessant R, Keat A (2002) How should clinicians manage osteoporosis in ankylosing spondylitis? J Rheumatol 29:1511–1519PubMed
14.
Zurück zum Zitat Speden DJ, Calin AI, Ring FJ et al (2002) Bone mineral density, calcanean ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol 29:516–521PubMed Speden DJ, Calin AI, Ring FJ et al (2002) Bone mineral density, calcanean ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol 29:516–521PubMed
15.
Zurück zum Zitat Toussirot E, Michel F, Wendling D (2001) Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. J Rheumatol 40:882–888CrossRef Toussirot E, Michel F, Wendling D (2001) Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. J Rheumatol 40:882–888CrossRef
16.
Zurück zum Zitat Gratacós J, Collado A, Pons F et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis. A follow-up study. Arthritis Rheum 42:2319–2324PubMedCrossRef Gratacós J, Collado A, Pons F et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis. A follow-up study. Arthritis Rheum 42:2319–2324PubMedCrossRef
17.
Zurück zum Zitat Maillefert JF, Aho LS, El Maghraoui A et al (2001) Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 12:605–609PubMedCrossRef Maillefert JF, Aho LS, El Maghraoui A et al (2001) Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 12:605–609PubMedCrossRef
18.
Zurück zum Zitat Bronson WD, Walker SE, Hillman LS et al (1998) Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis. J Rheumatol 25:929–935PubMed Bronson WD, Walker SE, Hillman LS et al (1998) Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis. J Rheumatol 25:929–935PubMed
19.
Zurück zum Zitat Toussirot E, Ricard-Blum S, Dumoulin G et al (1999) Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology 38:21–27PubMedCrossRef Toussirot E, Ricard-Blum S, Dumoulin G et al (1999) Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology 38:21–27PubMedCrossRef
20.
Zurück zum Zitat Mitra D, Elvis DM, Collins AJ (1999) Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relantionship with bone mineral density and vertebral fractures. J Rheumatol 26:2201–2204PubMed Mitra D, Elvis DM, Collins AJ (1999) Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relantionship with bone mineral density and vertebral fractures. J Rheumatol 26:2201–2204PubMed
21.
Zurück zum Zitat Borman P, Bodur H, Bingöl N et al (2001) Bone mineral density and bone turnover markers in a group of male ankylosing spondylitis patients: relationship to disease severity. J Clin Rheumatol 7:315–321PubMedCrossRef Borman P, Bodur H, Bingöl N et al (2001) Bone mineral density and bone turnover markers in a group of male ankylosing spondylitis patients: relationship to disease severity. J Clin Rheumatol 7:315–321PubMedCrossRef
22.
Zurück zum Zitat El Maghraoui A, Borderie D, Cherruau B et al (1999) Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol 26:2205–2209PubMed El Maghraoui A, Borderie D, Cherruau B et al (1999) Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol 26:2205–2209PubMed
23.
Zurück zum Zitat Franck H, Meurer T, Hofbauer LC (2004) Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in ankylosing spondylitis. J Rheumatol 31:2236–2241PubMed Franck H, Meurer T, Hofbauer LC (2004) Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in ankylosing spondylitis. J Rheumatol 31:2236–2241PubMed
Metadaten
Titel
Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis
verfasst von
Laura Muntean
Marena Rojas-Vargas
Pilar Font
Siao-Pin Simon
Simona Rednic
Ruxandra Schiotis
Simona Stefan
Maria M. Tamas
Horatiu D. Bolosiu
Eduardo Collantes-Estévez
Publikationsdatum
01.05.2011
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 5/2011
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-010-1648-3

Weitere Artikel der Ausgabe 5/2011

Clinical Rheumatology 5/2011 Zur Ausgabe

Original Article

Osteomalacia revisited

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.